Novartis Kisqali significantly reduced risk of recurrence by 25% across broad population of patients with early breast cancer: Novartis Ruchika Sharma4 Jun 2023 1:00 PM ISTBasel: Novartis has presented positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical...
Novartis Cosentyx gets European Commission nod for use in adults with hidradenitis suppurativa Ruchika Sharma1 Jun 2023 11:00 AM ISTA regulatory decision from the US Food and Drug Administration is expected later this year.
EMA panel recommends revocation of conditional marketing authorization for Novartis sickle cell disease medicine Adakveo MD Bureau27 May 2023 3:42 PM ISTBasel: Novartis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the...
New Sandoz Board of Directors appointed Ruchika Sharma15 May 2023 2:57 PM ISTBasel: The Novartis Board of Directors has approved the recommendations of the Sandoz Chairman-designate, Gilbert Ghostine, on the structure of the...
Submit serious adverse events, deaths occurred during CT: CDSCO Panel Tells Novartis on Ruxolitinib Dr. Divya Colin12 May 2023 6:00 PM ISTNew Delhi: With respect to the safety and efficacy data of global study and post-marketing data related to the Ruxolitinib tablets 5mg,10mg, 15mg, and...
Patent infringement: Amgen sues Novartis to block generic osteoporosis, bone cancer drugs Ruchika Sharma3 May 2023 5:30 PM ISTAmgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.
Novartis gets positive CHMP opinion for Cosentyx in adults with hidradenitis suppurativa Ruchika Sharma30 April 2023 10:00 AM ISTCosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of...
Novartis lifts full year earnings on higher prescriptions Ruchika Sharma25 April 2023 11:37 AM ISTFirst-quarter group sales gained 3 percent to $12.95 billion, above an analyst consensus of $12.55 billion, driven by better than expected revenues...
Novartis Millburn facility gets USFDA nod for US commercial production of Pluvicto Ruchika Sharma24 April 2023 2:15 PM ISTUnited States: Novartis has received US Food and Drug Administration (FDA) approval to begin supplying Pluvicto for US commercial use from the...
Novartis bid to revive multiple sclerosis drug Gilenya patent rebuffed by US Supreme Court Ruchika Sharma18 April 2023 12:30 PM ISTThe USFDA in 2010 approved Gilenya to treat relapsing forms of multiple sclerosis.
Cipla joins hands with Novartis Pharma AG to market diabetes drug Galvus in India Ruchika Sharma10 April 2023 3:10 PM ISTGalvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication...
Novartis Entresto receives positive CHMP opinion for pediatric heart failure Ruchika Sharma2 April 2023 2:00 PM ISTPediatric heart failure represents an important cause of morbidity and mortality in childhood.
